

正本

檔 號：  
保存年限：

## 新北市政府衛生局 函

地址：22006新北市板橋區英士路192-1號  
承辦人：姜俞臣  
電話：(02)22577155 分機1310  
傳真：(02)22572761  
電子信箱：ak9458@ntpc.gov.tw



24158

新北市三重區重新路5段646號8樓

受文者：新北市藥師公會

發文日期：中華民國104年7月8日  
發文字號：新北衛食字第1041214223號  
速別：普通件  
密等及解密條件或保密期限：  
附件：原函及相關資料影本各1份

主旨：檢送有關「VIAGRA」（批號B714830238）」及「Norditriopin Simplex 10 mg/1,5 ml（批號SC11255及CL70711）」不良品暨回收警訊相關資料，為維護國民之健康與安全，惠請轉知所屬會員，如有案內違規產品應立即下架勿販售，請查照。

說明：依據衛生福利部食品藥物管理署104年6月30日FDA企字第1041202864號函及104年6月30日FDA企字第1041202867號函辦理。

正本：新北市藥師公會  
副本：

# 局長 林奇宏

本案依分層負責規定授權業務主管決行

檔 號：  
保存年限：

## 衛生福利部食品藥物管理署 函

地址：11561 臺北市南港區昆陽街161-2號  
聯絡人：莊秉潔  
聯絡電話：02-27877243  
傳真：02-26532055  
電子信箱：dpqbdpqb@fda.gov.tw

受文者：新北市政府衛生局

發文日期：中華民國104年6月30日  
發文字號：FDA企字第1041202864號  
速別：普通件  
密等及解密條件或保密期限：  
附件：資料2份(104120286400-1.PDF、104120286400-2.pdf)

主旨：檢送案內所陳藥品「VIAGRA」（批號B714830238）」不良  
品暨回收警訊相關資料2份，為維護國民之健康與安全，  
請將該產品於市面可能販售及網路刊售之情事列入稽查工  
作重點，查明依法處辦，請查照。

說明：依據本署104年6月25日接獲美義大利AIFA - Product Qu  
ality and Counterfeiting Office經PIC/S Rapid Alert  
System通報藥品不良品暨回收警訊相關資料辦理。

正本：各縣市衛生局

副本：





AIFA/PQ&C/65182/P del 25/06/2015

RAPID ALERT NOTIFICATION OF A QUALITY DEFECT/RECALL		
IMPORTANT - DELIVER IMMEDIATELY		Ref. IT/I/1/01
1.To: (see list attached, if more than one)		
2.Product Recall Class of Defect:	3.Counterfeit / Fraud (specify)*: Counterfeit	
4.Product: VIAGRA	5.Marketing Authorisation Number:* For use in Humans/ <del>animal</del>	
6.Brand/Trade Name: VIAGRA	7.INN or Generic Name: SILDENAFIL	
8. Dosage Form: Tablets	9. Strength: 100 mg	
10.Batch/Lot Number: B714830238	11.Expiry Date: 04/2017	
12. Pack size and Presentation: 4 tablets	13. Date Manufactured:	
14. Marketing Authorisation Holder:	Illegal Product	
15. Manufacturer: Contact point:	16. Recalling Firm (if different):	
17. Recall Number Assigned (if available): Ref. IT/I/1/01		
18. Details of Defect/Reason for Recall: Falsified blister of Viagra 100 mg 4 tablets (without the secondary packaging and patient information leaflet) have been seized by the local branch Italian Custom located in Bari during the Operation Pangea VIII. The blisters showed the batch number B714830238 and the expiry date 04/2017. The marketing authorization holder of the original medicine has reported that the batch number do not correspond to a genuine batch manufactured by Pfizer. Samples of the falsified product are about to be sent to the Italian OMCL/MAH laboratories for further investigation and testing.		
19.Information on distribution including exports (type of customer, e.g. hospitals): possible distribution through <u>illegal channels</u> (EG sex shops, Internet).		
20. Action taken by Issuing Authority: communication to the general public through the official website.		
21.Proposed Action: Operators (EG non pharmaceutical shops owners)/customers in possession of packs of Viagra 100mg 4 tabs, batch number B714830238, expiry 04-2017 are requested to not distribute the product and to report immediately to AIFA.		
22.From (Issuing Authority): AIFA – Product Quality and Counterfeiting Office	23.Contact Person: Domenico Di Giorgio, Ph D. <a href="mailto:d.digiorgio@aifa.gov.it">d.digiorgio@aifa.gov.it</a> <a href="mailto:medicrime@aifa.gov.it">medicrime@aifa.gov.it</a>	
24.Signed: Domenico Di Giorgio 	25.Date: June 25, 2015	26.Time:*

檔 號：  
保存年限：

## 衛生福利部食品藥物管理署 函

地址：11561 臺北市南港區昆陽街161-2號  
聯絡人：莊東燦  
聯絡電話：02-27877243  
傳真：02-26532055  
電子信箱：dpqbdpqb@fda.gov.tw

受文者：新北市政府衛生局

發文日期：中華民國104年6月30日  
發文字號：FDA企字第1041202867號  
速別：普通件  
密等及解密條件或保密期限：  
附件：資料1份(104120286700-1.pdf)

主旨：檢送案內所陳藥品「Norditriopin Simplex 10 mg/1,5 ml (批號SC11255及CL70711)」不良品暨回收警訊相關資料1份，該等產品在波士尼亞與赫塞哥維納發現仿冒品流通，為維護國民之健康與安全，請將該產品於市面可能販售及網路刊售之情事列入稽查工作重點，查明依法處辦，請查照。

說明：依據本署104年6月27日接獲克羅埃西亞HALMED-Agency for Medicinal Products and Medical Devices of Croatia經PIC/S Rapid Alert System通報藥品不良品暨回收警訊相關資料辦理。


正本：各縣市衛生局


副本：



**IMPORTANT – DELIVER IMMEDIATELY**  
**Rapid Alert Notification of a Quality Defect / Recall**

Reference Number  
 HR/I/01/01

	
1. To: (see list attached, if more than one)	
2. Product Recall Class of Defect: (circle one)	<input checked="" type="radio"/> I <input type="radio"/> II <input type="radio"/> III
4. Product: Norditropin Simplex 10 mg/1,5 ml	3. Falsification*
6. Brand/Trade Name: Norditropin Simplex	5. Marketing Authorisation Number: * For use in humans
8. Dosage Form: solution for injection	7. INN or Generic Name: somatropin
10. Batch number (and bulk, if different): SC11255 CL70711	9. Strength: 10 mg/1,5 ml
12. Pack size and Presentation: unknown	11. Expiry Date: 11/ 2016 (SC 11255) 08/2017 (CL 70711)
14. Marketing Authorisation Holder: * Of original medicine Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Danmark	13. Date Manufactured: *
15. Manufacturer#: Novo Nordisk A/S, Novo Alle, DK-2880 Bagsvaerd, Danmark  Contact Person:  Telephone:	16. Recalling Firm (if different): <i>Reporting representative</i> Novo Nordisk Hrvatska d.o.o. Damira Tomljanovića Gavrana 17a 10020 Zagreb Croatia  Contact Person: Martina Kaić, MPharm  Telephone: 0997022033
17. Recall Number Assigned (if available): not applicable (internal case number 530-09/15-01/60)	
18. Details of Defect/Reason for Recall:  The Croatian affiliate has received a phone call about two suspected Norditropin SimpleXx 10 mg/1,5 ml counterfeit products (photo attached). The products are labelled as Norditropin SimpleXx from Novo Nordisk with batch number SC11255, expiry date 11/ 2016 and CL70711, expiry date 08/2017. A cartridge with batch number CL70711 was received for investigation by MAH. The complainant claimed that he got the product from a private pharmacy in the city of Banja Luka, Bosnia and Herzegovina. However the complainant was not willing to reveal the name and the address of the location. The text on the boxes is printed in Romanian language and boxes are concluded to be fake. The batch numbers and expiry dates are not valid production data used by Novo Nordisk.  There have been three earlier cases on batch number SC11255, two in Germany, one in Spain. Only the pictures were received for investigation for this case so Novo Nordisk was not able to perform an investigation.	

<p>There has been one earlier batch number on batch number CL70711 in UK. One sample was received for an investigation for the present case. Macroscopically and microscopically examinations were performed. The content in the sample was clear. One dark hair fibre appeared in solution approximately 1,5 ml was left in the cartridge. The rubber membrane did not originate from Novo Nordisk and there was no penetration mark in the rubber membrane. Furthermore the code cap is not from Novo Nordisk and the plunger is without silicone. There is a weak smell of phenol. It is not possible to detect somatropin in the cartridge. Based on the results of the investigation sample with batch number CL70711 is considered to be counterfeit.</p>		
<p>19. Information on distribution including exports (type of customer, e.g. hospitals): *</p> <p>No precise information is available.</p>		
<p>20. Action taken by Issuing Authority:</p> <p>Classification as Class I defect, information of RAS Inform Regulatory authority in Bosnia and Herzegovina</p>		
<p>21. Proposed Action: market action as needed</p>		
<p>22. From (Issuing Authority): Agency for Medicinal Products and Medical Devices (HALMED) Ksaverska cesta 4, Zagreb Croatia</p>		<p>23. Contact Person: Ana Boban, MPharm <a href="mailto:rapidalert.hr@halmed.hr">rapidalert.hr@halmed.hr</a> Telephone: + 385 99 263 7898</p>
<p>24. Signed:</p>  <p>Ana Boban 26.06.2015 21:05</p>	<p>25. Date: 26.06.2015.</p>	<p>26. Time: 21:05*</p>

\* Information not required, when notified from outside EU.

# The holder of an authorisation referred to under Article 40 of Directive 2001/83/EC or Article 44 of Directive 2001/82/EC and the holder of the authorisation on behalf of whom the Qualified Person has certified the batch for release in accordance with Article 51 of Directive 2001/83/EC or Article 55 of Directive 2001/82/EC if different.

*This is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under applicable law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please notify us by telephone immediately and return it to us at the above address by mail. Thank you*

\*\*\*\*\*